



## Altimune To Announce Year End 2020 Financial Results on February 25, 2021

February 22, 2021

GAITHERSBURG, Md., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Altimune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its full year 2020 financial results on Thursday, February 25<sup>th</sup>, 2021.

Altimune management will host a conference call for investors beginning at 8:30 am ET on Thursday, February 25<sup>th</sup>, 2021 to discuss financial results and provide a business update.

### Conference Call Information:

Date: Thursday, February 25, 2021  
Time: 8:30 am Eastern Time  
Domestic Dial-in: 877-423-9813  
International Dial-in: 201-689-8573  
Conference ID: 13716171  
Webcast: <http://public.viavid.com/index.php?id=143423>

### About Altimune

Altimune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). For more information on Altimune, please visit [www.altimmune.com](http://www.altimmune.com).

### Investor & Media Contacts:

Will Brown  
Chief Financial Officer  
Phone: 240-654-1450  
[wbrown@altimmune.com](mailto:wbrown@altimmune.com)

Stacey Jurchison  
Sr. Dir, Investor Relations  
Phone : 410-474-8200  
[sjurchison@altimmune.com](mailto:sjurchison@altimmune.com)



Source: Altimune, Inc.